Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein

European Journal of Pharmaceutical Sciences

Volumn 27, Issue 5, 2006, Pages 543-554

  Keogh, John P ^a   Kunta, Jeevan R ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Clinical; Digoxin; Drug drug interactions; P glycoprotein; P glycoprotein inhibition

Indexed keywords

ASTEMIZOLE; DIGOXIN; ELACRIDAR; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; QUINIDINE; QUININE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG INTERACTION; DRUG POTENCY; DRUG TRANSPORT; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REPRODUCIBILITY;

ANIMALS; ASTEMIZOLE; AUTOMATION; CELL LINE; DIGOXIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; KETOCONAZOLE; P-GLYCOPROTEIN; QUINIDINE; REPRODUCIBILITY OF RESULTS; TRANSFECTION; TRITIUM;

EID: 33644868785     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.11.011     Document Type: Article

References (45)

1. B. Angelin, A. Arvidsson, R. Dahlqvist, A. Hedman, and K. Schenck-Gustafsson Quinidine reduces biliary clearance of digoxin in man Eur. J. Clin. Invest. 17 3 1987 262 265
2. J.K. Aronson, and J.G. Carver Interaction of digoxin with quinine Lancet 1 1981 1418
3. T.D. Bjornsson, J.T. Callaghan, H.J. Einolf, V. Fischer, L. Gan, S. Grimm, J. Kao, S.P. King, G. Miwa, L. Ni, G. Kumar, J. McLeod, R.S. Obach, S. Roberts, A. Roe, A. Shah, F. Snikeris, J.T. Sullivan, D. Tweedie, J.M. Vega, J. Walsh, and S.A. Wrighton The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab. Dispos. 31 2003 815 832
4. P. Bolme, and U. Otto Dose-dependence of the pharmacokinetics of quinidine Eur. J. Clin. Pharmacol. 12 1 1977 73 76
5. R.A. Boyd, R.H. Stern, B.H. Stewart, X. Wu, E.L. Reyner, E.A. Zegarac, E.J. Randinitis, and L. Whitfield Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion J. Clin. Pharmacol. 40 1 2000 91 98
6. C. Chen, R.J. Mireles, S.D. Campbell, J. Lin, J.B. Mills, J.J. XU, and T.A. Smolarek Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2 and OATP1B1 Drug Metab. Dispos. 33 4 2005 537 546
7. K.J. Cooper, P.D. Martin, A.L. Dane, M.J. Warwick, D.W. Schneck, and M.V. Cantarini Effect of itraconazole on the pharmacokinetics of rosuvastatin Clin. Pharmacol. Ther. 73 4 2003 322 329
8. R. Ding, Y. Tayrouz, K.D. Riedel, J. Burhenne, J. Weiss, G. Mikus, and W.E. Haefeli Substantial pharmacokinetic interaction between digoxin and ritornavir in healthy volunteers Clin. Pharmacol. Ther. 76 1 2004 73 84
9. W. Doering Quinidine digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications N. Engl. J. Med. 301 1979 400 404
10. P. Dorian, M. Strauss, C. Cardella, T. David, S. East, and R. Ogilvie Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment Clin. Invest. Med. 11 2 1988 108 112
11. M.F. Fromm, R.B. Kim, C.M. Stein, G.R. Wilkinson, and D.M. Roden Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 1999 552 557
12. A. Hedman, B. Angelin, A. Arvidsson, R. Dahlqvist, and B. Nilsson Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine Clin. Pharmacol. Ther. 47 1 1990 20 26
13. A. Hedman, B. Angelin, A. Arvidsson, O. Beck, R. Dahlqvist, B. Nilsson, M. Olsson, and K. Schenck-Gustafsson Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans Clin. Pharmacol. Ther. 49 3 1991 256 262
14. J.H. Hochman, N. Pudvah, J. Qiu, M. Yamazaki, C. Tang, J.H. Lin, and T. Prueksaritanont Interactions of human P-glycoprotein with simvastatin, simvastatin acid and atorvastatin Pharm. Res. 21 9 2004 1686 1691
15. S. Ibrahim, J. Peggins, A. Knapton, T. Licht, and A. Aszalos Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation Anticancer Res. 21 2A 2001 847 856
16. E. Iisalo Clinical pharmacokinetics of digoxin Clin. Pharmacokin. 2 1977 1
17. K.M. Jalava, J. Partanen, and P.J. Neuvonen Itraconazole decreases renal clearance of digoxin Ther. Drug Monit. 19 6 1997 609 613
18. R.W. Jelliffe An improved method digoxin therapy Ann. Intern. Med. 69 1968 703
19. D.F. Kehrer, R.H. Mathijssen, J. Verweij, P. de Bruijn, and A. Sparreboom Modulation of irinotecan metabolism by ketoconazole J. Clin. Oncol. 20 14 2002 3122 3129
20. H.O. Klein, R. Lang, E. Weiss, E. Di Segni, C. Libhaber, J. Guerrero, and E. Kaplinsky The influence of verapamil on serum digoxin concentration Circulation 65 1982 998 1003
21. G. Koren, C. Woodland, and S. Ito Toxic digoxin-drug interactions: the major role of renal P-glycoprotein Vet. Hum. Toxicol. 40 1 1998 45 46
22. J.R. Koup, D.J. Greenblatt, W.J. Jusko, T.W. Smith, and J. Koch-Weser Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses J. Pharmacokin. Biopharm. 3 1975 181 192
23. J.M. Kovarik, L. Rigaudy, M. Guerret, C. Gerbeau, and K.L. Rost Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin Clin. Pharmcol. Ther. 66 4 1999 391 400
24. G.A. Kullak-Ublick, G.M. Ismair, B. Steiger, L. Landmann, R. Huber, F. Pizzagalli, K. Fattinger, P.J. Meier, and B. Hagenbuch Organic aniuon-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver Gastroenterology 120 2 2001 523 525
25. Lanoxin(R), digoxin product information. Glaxo Wellcome Inc., Research Triangle Park, NC (PI revised 11/98, reviewed 1/2000).
26. E.B. Leahey, J.A. Reiffel, R.E. Drusin, R.H. Heissenbuttel, W.P. Lovejoy, and J.T. Bigger Interaction between quinidine and digoxin JAMA-J. Am. Med. Assoc. 240 1978 533 534
27. R.A. Lefebvre, A. Van Peer, and R. Woestenborghs Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole Brit. J. Clin. Pharmacol. 43 3 1997 319 322
28. H. Lennernas Clinical pharmacokinetics of atorvastatin Clin. Pharmacokinet. 42 13 2003 1141 1160
29. T. Mikkaichi, T. Suzuki, T. Onogawa, M. Tanemoto, H. Mizutamari, M. Okada, T. Chaki, S. Masuda, T. Tokui, N. Eto, M. Abe, F. Satoh, M. Unno, T. Hishinuma, K. Inui, S. Ito, J. Goto, and T. Abe Isolation and characterisation of a digoxin transporter and its rat homologue expressed in the kidney Proc. Natl. Acad. Sci. U.S.A. 101 10 2004 3569 3574
30. R.A. Mirghani, U. Hellgren, L. Bertilsson, L.L. Gustafsson, and O. Ericsson Metabolism and elimination of quinine in healthy volunteers Eur. J. Clin. Pharmacol. 59 5-6 2003 423 427
31. J. Partanen, K.M. Jalava, and P.J. Neuvonen Itraconazole increases serum digoxin concentration Pharmacol. Toxicol. 79 5 1996 274 276
32. K.E. Pedersen, B.D. Christiansen, K. Kjaer, N.A. Klitgaard, and F. Nielsen-Kudsk Verapamil-induced changes in digoxin kinetics and intraerythrocytic sodium concentration Clin. Pharmacol. Ther. 34 1 1983 8 13
33. K.E. Pedersen, B.D. Christiansen, N.A. Klitgaard, and F. Nielsen-Kudsk Effect of quinidine on digoxin bioavailability Eur. J. Clin. Pharmacol. 24 1 1983 41 47
34. K.E. Pedersen, L.J. Masden, N.A. Klitgaard, K. Kjaer, and S. Hvidt Effect of quinine on plasma digoxin concentration and renal digoxin clearance Acta Med. Scan. 218 1985 229 232
35. J.W. Polli, S.A. Wring, J.H. Humphreys, L. Huang, J.B. Morgan, L.O. Webster, and C.S.S. Serabjit-Singh Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 299 2001 620 628
36. J. Rengelshausen, C. Goggelmann, J. Burhenne, K.D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack, and W.E. Haefeli Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-chlarithromycin interaction Brit. J. Clin. Pharmacol. 56 2003 32 38
37. W. Sawicki, and S. Janicki Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation Int. J. Pharm. 238 1-2 2002 181 189
38. E. Steiness, S. Waldorff, and P.B. Hansen Renal digoxin clearance dependence on plasma digoxin and diuresis Eur. J. Clin. Pharmacol. 23 1982 151 154
39. The Digitalis Investigation group The effects of digoxin on mortality and morbidityin patients with heart failure N. Engl. J. Med. 336 1997 525 533
40. T.T. Tran, A. Mittal, T. Gales, B. Maleeff, T. Aldinger, J.W. Polli, A. Ayrton, H. Ellens, and J. Bentz Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modelled as a single barrier J. Pharm. Sci. 93 8 2004 1 16
41. U.S. Food and Drug Administration, 2004. Drug interaction studies - study design, data analysis, and implications for dosing and labelling - preliminary concept paper. Available from the FDA website: http://www.fda.gov.
42. M. Verschraagen, C.H. Koks, J.H. Schellens, and J.H. Beijnen P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil Pharmacol. Res. 40 1999 301 306
43. M. Wandell, J.R. Powell, W.D. Hager, P.E. Fenster, P.E. Graves, K.A. Conrad, and S. Goldman Effect of quinine on digoxin kinetics Clin. Pharmacol. Ther. 28 4 1980 425 430
44. K. Westphal, A. Weinbrenner, T. Giessmann, M. Stuhr, G. Franke, M. Zschiesche, R. Oertel, P. Terhaag, H.K. Kroemer, and W. Siegmund Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvment of intestinal P-glycoprotein Clin. Pharmacol. Ther. 68 1 2000 6 12
45. W. Zilly, E. Richter, and N. Rietbrock Pharmacokinetics and metabolism of digoxin and B-methyl-digoxin-12a-3 H in patients with acute hepatitis Clin. Pharmacol. Ther. 17 1975 302 309